MUC16 and ovarian cancer: An assessment of ovarian cancer screening conducted in 1998 by the National Health Service Health Technology Assessment Programme based on a review of 25 ovarian cancer screening studies was that the routine use of cancer antigen 125 (CA125) serum testing and transvaginal ultrasound was unwarranted [3].